Member Info for crumbs

Trinity's funding forecasts...

'Looking ahead, for FY19 we expect the operating loss to widen to £8.6m, with the overall loss rising to £7.1m. This is driven by development costs forecast to grow to £6.1m, as clinical programmes start their ramp up. General and administrative expenses are expected to increase to £2.5m. For FY20 we expect these expenses to be just over £5.0m and £2.6m respectively, with an operating loss of £7.6m and overall loss of £6.4m. The reduction in R&D costs in FY20 is because of the costs of producing drug substances and other upfront costs associated with the clinical trials in the previous year. The resulting cash outflows mean we are expecting the cash position to be £4.3m at end-FY19 and so are forecasting a funding requirement of c £12m by FY20 (assuming spending on clinical programmes is maintained as planned).'

Yes

Both trials can now begin but it will not be enough money to complete both SCIB1 combo and modi1 trials however it does buy time that we were running low on...

'It is generally accepted that the enormous technological advances achieved by mankind in the 20th century not only changed the world beyond recognition, but were driven simultaneously by innovation and a fortunate combination of circumstances. To our minds, the progress achieved in the medical field in the 20th century did not match that in the world of pure technology, for a number of reasons, but we believe that this may be about to change.

It has long been evident that the research departments of large global pharmaceutical companies were not delivering the drug pipelines that these cash-rich companies required. The diverse technologies offered by smaller biotechnology companies are best-suited to provide new solutions to life-threatening and debilitating diseases both in the therapeutic and diagnostic space as they are more innovative and inherently more entrepreneurial. This will trigger not only aggressive acquisition of these technologies by big pharma, but also an era of rapid expansion in the biotechnology sector.

In the United States there is a well-established model for financing lifescience businesses through to success, but in Europe this does not exist to the same degree, even though the quality of the underlying science is often as good if not better.

There are opportunities in this often neglected area where one can find fundamentally undervalued technologies and businesses that offer an excellent long term risk/reward proposition.'

Sound like me but err with money :)

http://www.vulpesinvest.com/investment-focus/life-sciences/

With big holders now holding tight and a few of us smaller ones too City Investments out the way... not too much more positive newsflow would soon have this over 10p and beyond as the number of available shares becomes less and less .. the niggling doubt of funding is dealt with now well, for now, it is but in such a way as to make it look like any future needs will also get covered too... dilution is, of course, disappointing but this amount is acceptable and knowing scancell we know the funds will not be squandered and we soon have trials to be beginning and new data flowing in... A lot can now happen in our newly funded extra time to mean this could be the last such dilution this company ever needs to have......

'Scancell has announced that it has raised £3.877m (gross) through the issue of 77.6m new shares to Vulpes Life Sciences Fund at a price of 5p per share. The new investment results in Vulpes holding 16.67% of the enlarged share capital, overtaking Calculus Capital as the largest shareholder.
Vulpes Investment Management has a track record of identifying under-appreciated life sciences companies and then taking sizeable stakes. Importantly, they are supportive long-term holders. Martin Diggle, a founder of Vulpes in 2011, will join the Scancell board as a non-executive director.
The funds help extend Scancell’s cash runway, but it should be noted that the cash burn is expected to rise as it enters the more expensive clinical stages; our forecast is detailed in our Initiation note of November 2018.
It is worth highlighting that Scancell has two promising technology platforms for therapeutic vaccines that have the potential to treat many cancers, either as monotherapy or in combination with checkpoint inhibitors.
We feel that the timely development of these programmes has been hindered historically by financial issues. We view the Vulpes investment as a comforting sign that funding concerns appear to be being overcome.'

Exactly Evans and co tried to get them in back in 2015 to no avail so he is very impressed our BOD have pulled it off but lets face it scancell have a pipeline that could potentially fill a big pharma and data to prove that up will be incoming end of this year and all through next.... wonder what could be coming next... have no doubt today's news will have give some players a little shake

More impressive than all that though the first days buy on NEX was mine lol

David Evans has taken himself an extra 1 million shares today going off the lost island BB... seems very excited and looking forward to more news... obviously much to the chagrin of the doomers lol ....
Anyways really sets up scancell now and has bought us more time as well as brought in a very respected investor who will be able to attract and indeed contribute to any further needed raisings.. if we ever need one again that is... no one will be holding off doing a deal with scancell now thinking scancell are running on empty and that they can force our hand,

Know this could be the prelude to CRUK taking modi1 on all costs covered trial etc

Yes if we are to suffer the evil of dilution this is best way ...Seem a solid outfit and due diligence validation.......1 code over there worked it's magic too lol

Dale, I do not know if the FDA hold up is due to scancell not being a US company but possibly that is a factor... surely they would support the US company Ichor though? a company with US army contracts no less... also SCIB1 has US orphan status and I understand uses a US licensed component... whatever it is it is a very sad state of affairs for patients and no good to scancell Ichor or us poor pi... but I am at least heartened that scancell acted on it... we are led to believe Lindy wanted a UK arm to look at bloods... I'm sceptical of that I think the UK arm appeared only once there was an FDA knockback and their request for more info... then suddenly a UK arm appeared... well done scancell for that though we cannot afford to wait on big bureaucracy when the vaccine and the new device and most importantly the patients are ready and waiting... still hopeful the US arm of the trial will begin this year as it really is invaluable to have such esteemed clinicians and their top clinics involved positive data would not be ignored....

I'm not taking it seriously either though as Chester says such things seem to have an ability to influence sp just by sentiments... which of course then opens up the whole has someone done it on purpose question ...anyways all good fun and adds some interest that won't at least affect us here... unless it means we are getting an RNS lol... onwards...

Just for fun and us to observe from the safe distance but our fave other bio whos investors in we all love and have sometimes been had themselves one of those... 1 codes... will it does it mean something lol.. some there would like it to lets see then news for them tomorrow?.... I dunno but again we can watch at a safe distance and if nothing then nothing if something then confirmation bias lol...

I meant to add 'delivery' others disagree with me here but personally I think having to be tied to a third party electroporation device to deliver ImmunoBody has been a problem in getting deal/s on that platform... yes I know Pfizer has done a deal with Ichor as have J&J and inovio have managed to get themselves multiple pharma deals however I feel this layer of complexity has done SCIB1/ImmunoBody no favours and I think that is something scancell have taken on and CRUK have fully backed them in the taking up of nano-delivery... it is a reason I think scancell will get where they are going... they do not ever sit on their hands ever... FDA being arses... begin trial in UK this is a company that learns lessons... which being a science company you would... expect :)

Been a constant puzzle the no ability to finalise a deal on SCIB1... factors involved to my mind are... fashion...cancer vaccines went right out of fashion right at the moment SCIB1 data was looking freat due to Big pharma cancer vaccine huge failures (they invested in the wrong ones)) CI arrival that can be put a bit in fashion too but was very much backed by data...CI arrived and became the must-have assets despite them being of 20-30% effectiveness at best and toxicity issues.... can put personalised treatments in this bracket too CAR T's mRNA etc....scancells ImmunoBody just did not have the kind of outside support to get it a deal though we are told it came close... moditope completely different and has always attracted attention some of which we have seen ( BioNtech,Genentech and Karolinska) progress and understanding on that platform since it's discovery has been huge and not been an easy path to make it a clinically viable product but now with modi1 it is... MABs the market there already exists and we have seen is deemed of value to pharma... scancells glycan MABs novel and attractive with the likes of Seattle Genetics already being aware of them... We need a break no doubt about that and it needs an outside force to make a move in... ideally for me BioNtech on using modi tech in TCR use... none IP diluting money upfront and huge validation with valuation that AIM would get attached... but at least here there is more than just one chance on one product... again a pipeline with the combined potential of treating almost all cancer sufferers in almost all cancers at all stages ... that is potentially massive a big pharma in waiting.

What has not been priced in here...SCIB1 clinical yes that means in real human patients success... validated by the best clinicians in the world - Keith Flaherty et al... SCIB2 they have taken it on (all costs covered) to push it towards commercialisation in potentially multiple but first NSCLC target/s ....Glycan MABs and the platform tech attached that can come up with who knows how many targets...this is the kind of tech that we see big pharma deals done on in the last few days... Moditope... a platform that could eclipse CI and cell therapies (CAR T,TCR etc)..... basically this sp is just AIM mm's a few ii and not that many pi..... What happens when an outside force i.e respected Bio/Pharma puts a price on one piece of scancells tech in the form of a deal/s.... and that is only the beginning as then we have incoming data ....I think year on year the general appreciation of the kinds of techs scancell possess only increases... Frustrating at the beginning this but I think the rewards could play out to be incredible never seen before... just like the data ;)

pre last years raising began bringing in staff... notts uni people working under Lindy (students) who Lindy felt worthy this year the big guns Adrian and Samantha arrived ... I think there is very much a plan at play with sensible outcomes driving it... scancell have a pipeline that could potentially treat almost every cancer patient at every stage of their disease and possibly in combination mean they are 'cured'.... we are at the begining of a revolution that pharma has been slow to acknowledge the history of CI is not one of big pharma saying wow look at this we have come up with no... they got in on data and now it is the biggest thing in oncology treatment.... it is only the beginning....BioNtech 'get' scancell because BioNtech have similar roots.. apart from they got themselves huge financial backing from rich benifactors...... pi here have the chance to be in on something only the knowledgeable rich are already in on

You should read this... I think scancell are trying to do much the same .. and makes sense how we are now close to them:)

'But at the time, cancer vaccines were “considered as a crazy idea,” Tuereci recalled. “Pharma companies would not even deal with immune therapy concepts.”

The group turned its focus to what was then another new technology, monoclonal antibodies. In 2001, they founded Ganymed Pharmaceuticals AG, a name inspired by a Turkish word for “prize,” with Tuereci as CEO. Three years ago, Japanese drugmaker Astellas Pharma Inc. bought the company for as much as 1.2 billion euros ($1.4 billion).'

https://www.bloomberg.com/news/articles/2019-03-07/power-couple-behind-cancer-vaccine-rides-immune-oncology-success

Original scancell plan get data and sell to pharma on data.... we got data and did not sell(main reason being moditope arrived but also no one seemingly wanted SCIB1)... still to do a deal (ok CRUK SCIB2 is a deal but none upfront commercial) .... Our route seems to be a hard one but our assets look amazing...

Another Antibodies deal, yesterd\ay was Merck today J&J:

'Genmab and Johnson & Johnson have teamed up to develop a successor to their multiple myeloma blockbuster Darzalex. The deal gives J&J the option to license the asset after clinical proof of concept for $150 million (€132 million) plus milestones and royalties.

Anti-CD38 antibody Darzalex is one of the most successful new drugs of recent years, racking up $2 billion in sales last year. Genmab expects sales to hit $3 billion this year, and analysts at Jefferies think $10 billion is achievable in the long term. The sales targets reflect the potential for Darzalex to treat patients across the multiple myeloma pathway, particularly when a subcutaneous version is available.

Genmab and J&J are already looking beyond Darzalex, though. Researchers at Genmab have created a CD38 monoclonal antibody that uses HexaBody, a technology designed to dial up the cancer-killing power of therapeutics.'
https://www.fiercebiotech.com/biotech/j-j-bags-150m-option-genmab-s-darzalex-successor

Unless someone claims those trades we will never know... there was just under 2k in euros of volume on the Frankfurt exchange yesterday... someone seems to be building up a holding over there for whatever reasons but lets hope they work for BioNtech lol...wish it was a blue sky day but is looking very grey out.